Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
paper
Cited
Public
Unavailable
- Authors
- Neukirchen, Judith; Schoonen, Wilma M; Strupp, Corinna; Gattermann, Norbert; Aul, Carlo; Haas, Rainer; Germing, Ulrich
- Year
- 2011
- Journal
- Leukemia research
- PMID
- 21708407
- DOI
- 10.1016/j.leukres.2011.06.001
Population-based data on patients with MDS are scarce. Here we report the incidence and prevalence of MDS based on data from the Düsseldorf MDS Registry. Cases in the city of Düsseldorf in the study period were identified from the MDS Registry. We calculated crude, calendar-year, age- and sex-specific and European Standard Population age-standardized incidence rates as well as point prevalences per 100,000 The crude incidence rate was 4.15/100,000/year and the point prevalence per 100,000 persons of 7. We found that the incidence and prevalence of MDS was higher in men than women and increased sharply with increasing age.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | 2012 | 22561516 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Estimating the Causal Effect of Realistic Treatment Strategies Using Longitudinal Observational Data. | Zhang Y et al. | — | 2026 | → |
| Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study. | Kim I et al. | — | 2026 | → |
| Accelerated senescence of bone marrow erythrocyte precursors in myelodysplastic syndrome. | Liu M et al. | — | 2025 | → |
| Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome. | Bischof L et al. | — | 2025 | → |
| Burden of myelodysplastic syndromes: a systematic literature review of economic burden. | Tse P et al. | — | 2025 | → |
| Clinical management of CMML-State of the art. | Nachtkamp K et al. | — | 2025 | → |
| Contemporary CMML Risk Stratification and Management. | Sastow D et al. | — | 2025 | → |
| Inflammatory signaling in the pathogenesis of acute myeloid leukemia. | Baumann AM et al. | — | 2025 | → |
| Myelodysplastic syndromes: A primary care perspective. | Naidoo K et al. | — | 2025 | → |
| Navigating the New Era in Myelodysplastic Neoplasms: A Review of Prognostic Implications of the IPSS-M Score and 2022 WHO Classification. | Lapadat ME et al. | — | 2025 | → |
| Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis. | Rauhe KA et al. | — | 2025 | → |
| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS. | Rathje K et al. | — | 2025 | → |
| Perceptions and Needs of Stakeholders Regarding MyPal Project's Electronic Patient-Reported Outcome App: Cross-Sectional Qualitative Focus Group Study. | Kyrou D et al. | — | 2025 | → |
| Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes. | Adrianzen-Herrera DA et al. | — | 2025 | → |
| Structural Variant Analysis of Complex Karyotype Myelodysplastic Neoplasia Through Optical Genome Mapping. | Valkama A et al. | — | 2025 | → |
| The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms. | Kuszczak B et al. | — | 2025 | → |
| Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality. | Viayna E et al. | — | 2024 | → |
| A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes. | Boccia R et al. | — | 2024 | → |
| Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System. | Inoue Y et al. | — | 2024 | → |
| Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry. | Kasprzak A et al. | — | 2024 | → |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies. | Molica M et al. | — | 2024 | → |
| MDS patient registries - achievements and challenges. | Steinmetz T et al. | — | 2024 | → |
| Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the <i>TET2</i> Gene. | Danishevich A et al. | — | 2024 | → |
| Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). | Usuki K et al. | — | 2024 | → |
| Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). | Usuki K et al. | — | 2024 | → |
| Severe Acute Kidney Injury Associated with Transformation of Chronic Myelomonocytic Leukemia into Acute Myeloid Leukemia: A Case Report. | Lee SW et al. | — | 2024 | → |
| Validation of a novel algorithm with a high specificity in ruling out MDS. | Schulz F et al. | — | 2024 | → |
| An update on VEXAS syndrome. | Al-Hakim A et al. | — | 2023 | → |
| Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. | Beck DB et al. | — | 2023 | → |
| Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response. | Siamoglou S et al. | — | 2023 | → |
| Genomics of myelodysplastic/myeloproliferative neoplasm. | Patwardhan PP et al. | — | 2023 | → |
| Hematologic malignancies of primary bone marrow involvement: a decade's experience in Bahrain. | Ismaeel A et al. | — | 2023 | → |
| Significance of SF3B1 Mutations in Myeloid Neoplasms. | Gajzer DC et al. | — | 2023 | → |
| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents. | Pophali P et al. | — | 2023 | → |
| Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. | Sutandyo N et al. | — | 2022 | → |
| Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists. | Stojkov I et al. | — | 2022 | → |
| Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. | Cassanello G et al. | — | 2022 | → |
| The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. | Moyo TK et al. | — | 2022 | → |
| Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis. | Boquoi A et al. | — | 2022 | → |
| Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. | Zhou X et al. | — | 2021 | → |
| Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations. | Jiang Y et al. | — | 2021 | → |
| Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. | Tremblay D et al. | — | 2021 | → |
| Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A single-center report. | Wang X et al. | — | 2021 | → |
| Diagnosis and treatment of chronic myelomonocytic leukemia. | Kwon J | — | 2021 | → |
| Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes. | Pavlidis G et al. | — | 2021 | → |
| Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. | Crisà E et al. | — | 2021 | → |
| Genomic variations in patients with myelodysplastic syndrome and karyotypes without numerical or structural changes. | Ribeiro CL et al. | — | 2021 | → |
| Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? | Kasprzak A et al. | — | 2021 | → |
| Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. | Kuendgen A et al. | — | 2021 | → |
| Inflammasome Activation in Myeloid Malignancies-Friend or Foe? | Andina N et al. | — | 2021 | → |
| Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients. | Strapatsas J et al. | — | 2021 | → |
| Is Myelodysplasia a Consequence of Normal Aging? | Heibl S et al. | — | 2021 | → |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes. | Chan O et al. | — | 2021 | → |
| Myelodysplastic Syndromes and Metabolism. | Balaian E et al. | — | 2021 | → |
| Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†☆</sup>. | Fenaux P et al. | — | 2021 | → |
| MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. | Scarfò L et al. | — | 2021 | → |
| Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome. | Morelli E et al. | — | 2021 | → |
| The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. | Lauritsen TB et al. | — | 2021 | → |
| The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. | Delgado J et al. | — | 2021 | → |
| When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. | Bonadies N et al. | — | 2021 | → |
| [A monocentric study on the management of patients with myelodysplastic syndromes in Morocco]. | Maaroufi HE et al. | — | 2020 | → |
| Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. | Molga A et al. | — | 2020 | → |
| Controversies on the Consequences of Iron Overload and Chelation in MDS. | Vinchi F et al. | — | 2020 | → |
| Immuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation. | Sezaki M et al. | — | 2020 | → |
| Myelodysplastic syndromes: moving towards personalized management. | Hellström-Lindberg E et al. | — | 2020 | → |
| Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. | Carré M et al. | — | 2020 | → |
| Simplified flow cytometry scoring for diagnosis and prognosis of myelodysplastic symptom. | Guo J et al. | — | 2020 | → |
| An update on treatment of higher risk myelodysplastic syndromes. | Rahmé R et al. | — | 2019 | → |
| Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. | Park S et al. | — | 2019 | → |
| EASIX for prediction of survival in lower-risk myelodysplastic syndromes. | Merz A et al. | — | 2019 | → |
| Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. | Zeidan AM et al. | — | 2019 | → |
| Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. | Bastida JM et al. | — | 2019 | → |
| Liquid biopsies in myeloid malignancies. | Abdulmawjood B et al. | — | 2019 | → |
| Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. | Prusila REI et al. | — | 2019 | → |
| Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. | Hwang SM et al. | — | 2019 | → |
| Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. | Germing U et al. | — | 2019 | → |
| Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. | Montes P et al. | — | 2019 | → |
| A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. | Boutault R et al. | — | 2018 | → |
| Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? | Shenoy N et al. | — | 2018 | → |
| Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. | Malouf R et al. | — | 2018 | → |
| Diagnostic algorithm for lower-risk myelodysplastic syndromes. | Mufti GJ et al. | — | 2018 | → |
| Lobectomy for lung cancer in a myelodysplastic syndrome patient with decreasing platelet aggregation: report of a case. | Koezuka S et al. | — | 2018 | → |
| The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. | Castelli R et al. | — | 2018 | → |
| Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. | Heidenreich S et al. | — | 2017 | → |
| A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry. | Mayer F et al. | — | 2017 | → |
| Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. | Drozd-Sokołowska JE et al. | — | 2017 | → |
| Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. | Anwar N et al. | — | 2017 | → |
| Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. | Stahl M et al. | — | 2017 | → |
| Myelodysplastic Syndromes and Iron Chelation Therapy. | Angelucci E et al. | — | 2017 | → |
| New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. | Strupp C et al. | — | 2017 | → |
| Personalized treatment strategies for elderly patients with myelodysplastic syndromes. | Castelli R et al. | — | 2017 | → |
| Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). | Almeida A et al. | — | 2017 | → |
| Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. | Fenaux P et al. | — | 2017 | → |
| Techniques for detecting chromosomal aberrations in myelodysplastic syndromes. | Song Q et al. | — | 2017 | → |
| Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. | Bonadies N et al. | — | 2017 | → |
| A case of mandibular osteomyelitis in a patient with chronic myelomonocytic leukaemia. | Kojima Y et al. | — | 2016 | → |
| Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan. | Sultan S et al. | — | 2016 | → |
| Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. | Desborough M et al. | — | 2016 | → |
| Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review. | Desborough M et al. | — | 2016 | → |
| Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. | Ashraf A et al. | — | 2016 | → |
| Does Indian Myelodysplastic Syndrome Have a Biology Different from That in the West ? | Chaubey R et al. | — | 2016 | → |
| Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. | Kovtonyuk LV et al. | — | 2016 | → |
| Laboratory and clinical risk assessment to treat myelodysplatic syndromes. | Gidaro A et al. | — | 2016 | → |
| Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. | Roman E et al. | — | 2016 | → |
| New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. | Abou Zahr A et al. | — | 2016 | → |
| New insights into transfusion-related iron toxicity: Implications for the oncologist. | Porter JB et al. | — | 2016 | → |
| A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. | Otrock ZK et al. | — | 2015 | → |
| Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. | Abou Zahr A et al. | — | 2015 | → |
| Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. | Gu Y et al. | — | 2015 | → |
| Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. | Gu Y et al. | — | 2015 | → |
| Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes. | Xiong H et al. | — | 2015 | → |
| Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome. | Zhao WH et al. | — | 2015 | → |
| Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. | Hejazi M et al. | — | 2015 | → |
| Incidence and Burden of the Myelodysplastic Syndromes. | Cogle CR | — | 2015 | → |
| Myelodysplastic syndromes in South America: a multinational study of 1080 patients. | Belli CB et al. | — | 2015 | → |
| Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. | Burgstaller S et al. | — | 2015 | → |
| The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. | Petrou E et al. | — | 2015 | → |
| The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. | Dinmohamed AG et al. | — | 2015 | → |
| Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. | Breccia M et al. | — | 2014 | → |
| Incidence of myelodysplastic syndrome in Japan. | Chihara D et al. | — | 2014 | → |
| Myelodysplastic syndromes. | Adès L et al. | — | 2014 | → |
| Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Fenaux P et al. | — | 2014 | → |
| Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. | Bach V et al. | — | 2014 | → |
| Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. | Dinmohamed AG et al. | — | 2014 | → |
| Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. | McQuilten ZK et al. | — | 2014 | → |
| Why has demand for platelet components increased? A review. | Estcourt LJ | — | 2014 | → |
| Beyond race-related disparities: is myelodysplastic syndrome the same everywhere? | Magalhaes SM et al. | — | 2013 | → |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. | Malcovati L et al. | — | 2013 | → |
| Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. | Syed YY et al. | — | 2013 | → |
| Myelodysplastic syndromes: diagnosis, prognosis, and treatment. | Germing U et al. | — | 2013 | → |
| [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification]. | Schmitt-Graeff AH et al. | — | 2013 | → |
| Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. | Osca-Gelis G et al. | — | 2013 | → |
| Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. | Okuyama N et al. | — | 2013 | → |
| Proposed score for survival of patients with myelodysplastic syndromes. | Sperr WR et al. | — | 2013 | → |
| Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. | Nolte F et al. | — | 2013 | → |
| The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. | Gattermann N et al. | — | 2013 | → |
| The incidence of myelodysplastic syndromes in Western Greece is increasing. | Avgerinou C et al. | — | 2013 | → |
| The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? | Otrock ZK et al. | — | 2013 | → |
| Detectable clonal mosaicism from birth to old age and its relationship to cancer. | Laurie CC et al. | — | 2012 | → |
| Myelodysplastic syndrome in New Zealand and Australia. | Rodger EJ et al. | — | 2012 | → |
| The long term risk of myelodysplastic syndromes among anemia patients: a population-based study. | Meytes D et al. | — | 2012 | → |
| What's all the fuss about? facts and figures about bone marrow failure and conditions. | Mukherjee S et al. | — | 2012 | → |
| Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. | Craig BM et al. | — | 2011 | → |
| [Myelodysplastic syndromes]. | Solary E et al. | — | 2010 | → |